#STOPACEI#RCT
In our practice, we prescribe RAS blockers to slow down the progression of stage 4 and 5 CKD (Not on RRT) as these have been shown to be beneficial both theoretically and practically. Recently STOP ACEi TRIAL showed that there is no statistically significant difference whether you continue RAS blockers or discontinue them. There is no difference in decline in GFR in both arms and no difference in the need for renal replacement therapy.
This study was conducted at multiple sites in the UK and it is an open-label study. Participants were randomized in 1: 1 ratio in both arms. The primary outcome was a decline in GFR at 3 years follow up and secondary outcomes were the development of ESRD, a composite of decrease of eGFR of 50% or more or the initiation of RRT, hospitalization, blood pressure, exercise capacity, and quality of life.
conclusion: no difference between the two arms.

0 Comments

Up next

Autoplay

Are antidepressants effective for chronic pain? | 9 News Australia

1 Views . 08/29/25 Side Effects

Please note that if you are under 18, you won't be able to access this site.

Up next

STOP ACE trial (RAS inhibition in advanced chronic kidney disease)

Up next

Language